Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 12,000 shares at $2.96 ($35K) on 2014-07-07, disclosed to the SEC on 2014-07-09.
Scheduled sale ($35k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.82 | 300 | $846 | 2.4% |
| 2 | $2.82 | 500 | $1K | 4.1% |
| 3 | $2.84 | 100 | $284 | 0.8% |
| 4 | $2.84 | 800 | $2K | 6.5% |
| 5 | $2.85 | 1,000 | $3K | 8.2% |
| 6 | $2.85 | 900 |
| $3K |
| 7.4% |
| 7 | $2.86 | 500 | $1K | 4.1% |
| 8 | $2.86 | 600 | $2K | 4.9% |
| 9 | $2.87 | 200 | $574 | 1.7% |
| 10 | $2.88 | 600 | $2K | 5.0% |
| 11 | $2.90 | 600 | $2K | 5.0% |
| 12 | $2.92 | 1,700 | $5K | 14.3% |
| 13 | $2.93 | 900 | $3K | 7.6% |
| 14 | $2.93 | 1,700 | $5K | 14.3% |
| 15 | $2.94 | 200 | $588 | 1.7% |
| 16 | $2.94 | 600 | $2K | 5.1% |
| 17 | $2.96 | 600 | $2K | 5.1% |
| 18 | $2.96 | 200 | $592 | 1.7% |
| Total | $2.89 avg | 12,000 | $35K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |